Nebenwirkungen · Ituxredi
Ituxredi 100 mg concentrate for solution for infusion Ituxredi 500 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 20
HOS-152135 · Präparat HOS-100701
IgG levels In the clinical trial evaluating rituximab maintenance treatment in relapsed/refractory follicular lymphoma, median IgG levels were below the lower limit of normal (LLN) (< 7 g/L) after induction treatment in both the observation and the rituximab groups. In the observation group, the median IgG level subsequently increased to above the LLN but remained constant in the rituximab group. The proportion of patients with IgG levels below the LLN was about 60% in the rituximab group throughout the 2 year treatment period, while it decreased in the observation group (36% after 2 years).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-09T10:02:28Z · SHA-256 65f947c73c59460b3d1812ff80010d6719d500cc410ebccf88cf20b48b9c9fe9 · Passage f74cbc1ee340d802b6c265bd46f3e52314a929829a3c37d137a0f9cc70113286 · Zeichen 21986–22584 im Abschnitt